AFRO-NETS> GlaxoSmithKline African Malaria Partnership

[Dieter Neuvians MD <neuvians@mweb.co.zw>]

GlaxoSmithKline African Malaria Partnership
-------------------------------------------
Source: <tdr-scientists@who.ch>

GLAXOSMITHKLINE ANNOUNCES NEW COMMUNITY INITIATIVE FOR MALARIA IN 
AFRICA

London, 25 April 2002 - Pharmaceutical Company GlaxoSmithKline (GSK) 
is demonstrating its commitment to communities affected by malaria by 
launching a funding programme designed to 'kick-start' scale-up of 
activities in malaria control.

Focusing on Africa, where the greatest disease burden and the vast 
majority of malaria deaths occur, GSK's African Malaria Partnership 
(AMP) will award grants totalling US$ 1.5 million over three years to 
three community-focussed behavioural development programmes. By pro-
viding three years of funding, AMP grants will allow innovative and 
effective concepts to become established and to demonstrate further 
success. The aim will be to leverage this success to attract addi-
tional funding for further scale-up so t hat programmes can be ex-
panded and/or replicated elsewhere.

"GSK is major producer of medicines that treat malaria and is con-
stantly researching new and better vaccines and treatments," says Dr 
Richard South, director of GSK's malaria community partnership pro-
grammes. "But we recognise that other initiatives are also needed 
which is why we are launching the African Malaria Partnership. Around 
90 per cent of the 300-500 million cases of malaria that occur each 
year are in Africa, making it the area of greatest need. This is why 
GSK has chosen to focus its malaria com munity partnership efforts 
there."

National Malaria Control Programmes (NMCPs) in all malaria-affected 
African countries will be invited to submit a proposal for funding. 
Not-for-profit organisations can also submit proposals but must do so 
via the relevant NMCP. Non-profit programme proposals that relate to 
more than one country must also indicate that any relevant NMCP en-
dorsement of the proposal has been obtained. Involving the NMCP as a 
key partner will ensure that programme proposals form part of an in-
tegrated malaria control strategy.

GlaxoSmithKline - one of the world's leading research-based pharma-
ceutical and healthcare companies - is committed to improving the 
quality of human life by enabling people to do more, feel better and 
live longer. For company information and further information on the 
African Malaria Partnership, visit GSK on the World Wide Web at:
http://www.gsk.com

For further information, please contact 
Mark Watkins:
Tel: +44-20-8047-5525
or
Tel: +44-1279-644-427

--
To send a message to AFRO-NETS, write to: afro-nets@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe afro-nets OR unsubscribe afro-nets
To contact a person, send a message to: afro-nets-help@usa.healthnet.org
Information and archives: http://www.afronets.org